Keylicon Biosciences

Executive Summary

Keylicon Biosciences is a San Diego-based biotechnology company founded in 2018, developing next-generation self-amplifying RNA (saRNA) vaccines and therapies. The company's platform is designed to overcome the limitations of conventional mRNA by enabling longer-lasting protein expression from lower doses, potentially improving durability, potency, and safety. By leveraging saRNA technology, Keylicon aims to create versatile RNA-based medicines applicable to infectious diseases, oncology, and rare genetic disorders. While the company remains in early stages with no disclosed pipeline or funding, its focus on a differentiated RNA platform positions it in a competitive and rapidly evolving field. With growing interest in RNA therapeutics post-pandemic, Keylicon's approach could attract strategic partnerships or investment as it advances toward preclinical validation.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data60% success
• TBDSeries A Funding Round50% success
• TBDPharma Partnership or Licensing Deal40% success